Clinical Trial Update: Besponsa Post Marketing Surveillance Study

View source ↗

Summary

A post-marketing surveillance study of Besponsa (inotuzumab ozogamicin) by Pfizer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Pfizer | Conditions: Hematologic Malignancy | Status: COMPLETED | Results posted: 2025-12-31